[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336715-105":59,"doc-detail-336715-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","protocol-for-health-risk-information-technology-assisted-genetic-evaluation-heritage-randomised-controlled-trial-of-digital-genetic-cancer-risk-assessment-in-a-diverse-underserved-gynaecology-clinic","Protocol for Health Risk Information Technology-Assisted Genetic Evaluation (HeRITAGE) - Randomised Controlled Trial of Digital Genetic Cancer Risk Assessment in a Diverse Underserved Gynaecology Clinic","","Introduction: In the USA, up to 95% of people with cancer-predisposing germline pathogenic variants remain unidentified despite primary-care screening recommendations. Methods and analysis: A two-arm, single-institution randomised controlled trial compares a digital tool versus clinician interview for genetic cancer risk assessment. Eligible patients (≥18 years, English-speaking/reading, no prior testing, smartphone access) meet National Comprehensive Cancer Network criteria. Primary outcome evaluates testing recommendations; secondary outcomes include testing completion and patient-factor effects, especially social determinants of health. Ethics and dissemination include IRB approval, deidentified academic dissemination, and no direct trial-result notifications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/protocol-for-health-risk-information-technology-assisted-genetic-evaluation-heritage-randomised-controlled-trial-of-digital-genetic-cancer-risk-assessment-in-a-diverse-underserved-gynaecology-clinic/336715/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/protocol-for-health-risk-information-technology-assisted-genetic-evaluation-heritage-randomised-controlled-trial-of-digital-genetic-cancer-risk-assessment-in-a-diverse-underserved-gynaecology-clinic/336715.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the primary objective of the HeRITAGE randomised controlled trial?","Question",{"text":112,"@type":113},"To compare the proportion of eligible patients recommended for genetic testing for hereditary cancer syndromes using a digital tool versus a clinician interview in an urban academic gynaecology clinic.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which patients are eligible to participate in the study?",{"text":117,"@type":113},"Patients are eligible if they are 18 or older, speak and read English, have not had hereditary cancer genetic testing, meet National Comprehensive Cancer Network guideline criteria, and have access to a smartphone.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the primary outcome and how will it be analysed?",{"text":121,"@type":113},"The primary outcome is the proportion of eligible individuals recommended genetic testing in the digital tool arm versus usual care. It will be analysed using the χ2 test or Fisher’s exact test as appropriate.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336715,1790461193,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Open access Protocol  \n Protocol for Health Risk Information  \nTechnology-Assisted Genetic Evaluation (HeRITAGE): a randomised controlled trial of digital genetic cancer risk assessment in a diverse underserved gynaecology clinic  \nLeslie E Bull  ,1 Emily M Webster,1 Auja McDougale,1 Denise Howard,2 Muhammad Danyal Ahsan,1 Sarah Levi,3 Benjamin Grant,1 Isabelle Chandler,1 Paul Christos,4 Ravi N Sharaf,1 Melissa K Frey1  \nTo cite: Bull LE, Webster EM, McDougale A, et al. Protocol for Health Risk Information Technology-Assisted Genetic Evaluation (HeRITAGE):  \na randomised controlled trial of digital genetic cancer risk assessment in a diverse underserved gynaecology clinic. BMJ Open  \n2024;14:e082658 . doi:10 . 1136/ bmjopen-2023-082658  \n► Prepublication history for this paper is available online. To view these files, please visit the journal online ([https://doi](https://doi). org/10 . 1136/bmjopen-2023- 082658) .  \nLEB and EMW are joint first authors.  \nReceived 30 November 2023 Accepted 30 July 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nEmily M Webster;  \n[ew2485@cumc.columbia.edu](ew2485@cumc.columbia.edu)  \nABSTRACT  \nIntroduction In the USA, up to 95% of individuals harbouring cancer-predisposing germline pathogenic variants have not been identified despite recommendations for screening at the primary care level.  \nMethods and analysis Our primary objective is to use a two-arm, single-institution randomised controlled  \ntrial to compare the proportion of eligible patients that are recommended genetic testing for hereditary cancer syndromes using a digital tool versus clinician interview for genetic cancer risk assessment in an urban academic gynaecology clinic. New gynaecology patients will be consented and randomised 1:1 to either the intervention arm, in which a digital tool is used for genetic cancer risk assessment, or usual care, in which the clinician performs genetic cancer risk assessment. Individuals will be considered eligible for hereditary cancer syndrome genetic testing if criteria set forth by the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology are met. Eligible patients are 18 years or older, speak and read English, have not yet undergone hereditary cancer genetic testing and have access to a smartphone. The study aims to enrol 50 patients in each arm to allow for 80% power with two-tailed alpha of 5% to detect a 20% difference in proportion of eligible patients recommended for genetic testing. The primary outcome is the proportion of eligible individuals recommended genetic testing in the digital tool arm versus usual care arm, analysed using the χ2 or Fisher’s exact test as appropriate for sample size. The secondary outcome is completion of genetic testing, as well as exploration of patient factors, particularly social determinants of health, which may affect the receipt, utilisation and experience with genetic services.  \nEthics and dissemination This study has been approved by the Weill Cornell Institutional Review Board (Protocol No. 21-11024123) . Participants will be informed of the benefits and risks of participation prior to consent. Dissemination of data will be deidentified and conducted through academic conferences and journals. Patients identified to be eligible for genetic testing who did not  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ Randomised controlled design and comparison to usual care allows for evaluation of the impact a digital risk stratification tool may have on increasing counselling for patients eligible for genetic testing.  \n⇒ Study site at a racially and ethnically diverse, Medicaid-predominant clinic with a goal of capturing populations that have been historically underserved regarding genetic care.  \n⇒ Broad inclusion criteria were used to optimise generalisability. H","cbCainAOsIBaK0O4","https://ap.wps.com/l/cbCainAOsIBaK0O4","pdf",765001,"English","# Abstract\n## Introduction\n## Methods and analysis\n## Ethics and dissemination\n# Strengths and limitations of this study\n# Registration details and trial context\n# Introduction\n## Hereditary cancer syndromes and burden of unidentified variants\n## Family history as a cornerstone of risk assessment","[{\"question\":\"What is the primary objective of the HeRITAGE randomised controlled trial?\",\"answer\":\"To compare the proportion of eligible patients recommended for genetic testing for hereditary cancer syndromes using a digital tool versus a clinician interview in an urban academic gynaecology clinic.\"},{\"question\":\"Which patients are eligible to participate in the study?\",\"answer\":\"Patients are eligible if they are 18 or older, speak and read English, have not had hereditary cancer genetic testing, meet National Comprehensive Cancer Network guideline criteria, and have access to a smartphone.\"},{\"question\":\"What is the primary outcome and how will it be analysed?\",\"answer\":\"The primary outcome is the proportion of eligible individuals recommended genetic testing in the digital tool arm versus usual care. It will be analysed using the χ2 test or Fisher’s exact test as appropriate.\"}]","Protocol for Health Risk Information Technology-Assisted Genetic Evaluation (HeRITAGE) - Randomised Controlled Trial of Digital Genetic Cancer Risk Assessment in a Diverse Underserved Gynaecology Clinic | PDF",1790016340,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a274bb79bc8b3004ae7a618b5f02ebc7.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6355f25e3145aad8ca68689b3f0b30ee.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88a8a6cddd3106ce845dd762e9b83a34.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcc501b9053bfc28b39bc91aa9086afb.webp",980,1306]